Templates / Triglyceride Medication List

Metabolic Health

Triglyceride Medication List

Free PDF • 2 pages, print-ready • Clinician-reviewed

Despina Petrushevska Last updated September 11, 2026 Reviewed by Dr. Vanja Kitanova

---

A triglyceride medication list sets out every drug class used for hypertriglyceridemia, with dosing, expected reduction, and monitoring in one place. Fibrates lead on potency at 40 to 60 percent. Omega-3 medications and niacin follow at 20 to 50 percent, and statins contribute 10 to 30 percent.

This page carries those figures, the thresholds that trigger treatment, the ICD-10 codes, and a printable form for the patient record. Pharmacists, nurses, primary care physicians, and practice managers can use it as a prescribing reference.

Template details

Format

Printable PDF, 2 pages

Sections

5 sections

Fields to complete

2 fields

Best for

Metabolic Health

Key takeaways

Fibrates such as fenofibrate and gemfibrozil lower triglycerides by 40 to 60 percent and open most treatment plans.

Icosapent ethyl (Vascepa) is the only omega-3 medication with a cardiovascular outcome benefit, shown in REDUCE-IT.

Niacin still lowers triglycerides, but it added no cardiovascular benefit on top of statin therapy in AIM-HIGH and HPS2-THRIVE.

Gemfibrozil raises statin exposure, so fenofibrate is the safer fibrate to pair with a statin.

Practice management software like Pabau holds the list in the patient record, so prescribers read it where they prescribe.

What is a triglyceride medication list?

A triglyceride medication list is a structured clinical reference that groups the drugs used for hypertriglyceridemia by class. Each entry carries the generic and brand name, the mechanism, the typical dose, the expected reduction, contraindications, and the monitoring the drug requires.

A downloadable form does what a web page cannot. You can add your practice’s own protocols, file the completed sheet with the patient record, and revise it when guidance or the market changes.

Treatment decisions in the United States follow the ACC/AHA cholesterol guideline and the AAFP guidance on managing hypertriglyceridemia. Coding follows the same record: E78.1 covers pure hyperglyceridemia and E78.5 covers unspecified hyperlipidemia.

How to use the reference in your practice

Putting the form to work in a practice takes five steps.

1. Import the template. Download the PDF and store it in your clinical documentation system, or load it into the digital forms platform your practice already uses.
2. Customize the drug fields. Add your preferred fibrate brand, your omega-3 formulation, and any dosing protocol specific to your site.
3. Attach it to the patient record. File the completed sheet where the next prescriber will look, so the current regimen travels with the lipid panel.
4. Brief the team. Walk prescribers, nurses, and administrative staff through the layout and the statin-fibrate interaction warning.
5. Review it every year. Check it against current ACC/AHA guidance and FDA prescribing information, then add any agent newly approved in the United States.

Triglyceride thresholds and when to start medication

The measured level is the first decision point. These are the classifications used across US practice:

Medication usually starts when two to three months of lifestyle change has not moved the number. It also starts when the baseline sits above 200 mg/dL and cardiovascular risk factors are present. Prescription management systems track those thresholds and flag the dose review when the next panel lands.

Triglycerides rarely move on their own, so read the result beside the patient’s LDL and HDL. Our cholesterol level chart sets out those bands by age for the same conversation.

ICD-10 codes for hypertriglyceridemia

Two codes carry most of this work. E78.1 is pure hyperglyceridemia, and E78.5 is hyperlipidemia, unspecified. Coders reach for E78.1 when the record documents raised triglycerides on their own, and E78.5 when triglycerides form part of a mixed dyslipidemia.

Verify both against the CMS ICD-10-CM official guidelines for the current fiscal year, since descriptions and hierarchies change annually. The medication list supports that coding by showing what was prescribed, at what dose, and why.

Fibrates: first-line agents for high triglycerides

Fibrates are peroxisome proliferator-activated receptor (PPAR) agonists, and they remain the most potent triglyceride-lowering agents at 40 to 60 percent. The two prescribed most often are fenofibrate (Tricor, Trilipix) and gemfibrozil (Lopid).

Fenofibrate is the preferred partner when a statin is already in place. Gemfibrozil inhibits the glucuronidation of several statins and blocks OATP1B1-mediated hepatic uptake. Both effects raise statin plasma levels and, with them, the risk of myopathy.

Pemafibrate, a selective PPAR-alpha modulator, is sometimes mentioned as the next fibrate. It is approved in Japan and not in the United States, and its 2022 PROMINENT trial found no cardiovascular benefit. Leave it off a US list.

Dosing: fenofibrate is typically 145 mg daily with food, and gemfibrozil 600 mg twice daily. Monitoring: baseline liver function tests and creatine kinase, repeated at 6 to 12 weeks. Watch for myalgia, raised liver enzymes, and gallstones. Check renal function too, because the dose drops in severe impairment (eGFR below 30).

Take fenofibrate with food at a consistent time each day. The hour does not change how well it works, which sets it apart from statins, where evening dosing can matter.

Omega-3 fatty acid medications

Two prescription omega-3 products are on the US market: icosapent ethyl (Vascepa) and omega-3-acid ethyl esters (Lovaza). Both lower triglycerides by 20 to 50 percent, largely by reducing hepatic triglyceride synthesis. Epanova, the omega-3 carboxylic acid product, was withdrawn from the US market in 2020, so it belongs on no current list.

Vascepa is the only one with a cardiovascular outcome claim. The REDUCE-IT trial reported a 25 percent reduction in major adverse cardiovascular events. Lovaza has no equivalent outcome evidence.

Dosing: both need 4 g daily, in divided doses, for the full effect. Side effects stay mild, usually gastrointestinal upset and a fishy aftertaste, though the pill burden costs you adherence. All omega-3 agents carry a small bleeding risk, so use them carefully alongside anticoagulants.

Niacin and statins: secondary options

Niacin (nicotinic acid) lowers triglycerides by 20 to 50 percent, but prescribing collapsed after two trials. AIM-HIGH in 2011 and HPS2-THRIVE in 2014 both found no added cardiovascular benefit when niacin was layered onto statin therapy.

The Niaspan brand has since been discontinued, so any extended-release niacin you prescribe today is a generic. It remains an option for patients who tolerate neither fibrates nor omega-3 agents, and it is no longer a first-line recommendation.

Statins lower triglycerides by 10 to 30 percent as a secondary effect, with LDL reduction as their main indication. Atorvastatin and rosuvastatin do more for triglycerides than pravastatin or lovastatin, which makes them useful in mixed dyslipidemia.

Set side by side, the four classes separate clearly on potency.

Side effects and monitoring by drug class

Fibrates need baseline and periodic liver function tests, a creatine kinase measurement, and renal assessment. The main safety concern is myopathy in combination with a statin, and gemfibrozil carries the higher risk. Monitor creatine kinase closely in any combination regimen.

Omega-3 agents are well tolerated, with a mild increase in bleeding risk worth raising with anticoagulated patients. Niacin causes flushing often enough that aspirin pre-dosing is routine, and it can raise uric acid and glucose. Document any history of gout or diabetes before starting it.

Statins carry the familiar myopathy and liver enzyme risk, so baseline creatine kinase and liver function tests are standard. Recording each result against the medication that prompted it is what keeps a titration cycle auditable months later.

Prescribing workflows and practice integration

A reference only prevents errors if it sits inside the workflow. When a lipid panel comes back raised, four steps turn the result into a documented decision.

• Confirm the classification against the threshold table above.
• Select the first-line agent using comorbidities, interactions, and what the patient will tolerate.
• Document the drug, the dose, and the monitoring plan in the patient record.
• Book the follow-up lipid panel for 6 to 12 weeks at the moment of prescribing.

Metabolic and lipid clinics that manage this at volume usually keep the reference inside their weight loss clinic software, next to the record it informs. One current regimen per patient means fewer duplicate prescriptions and fewer missed interactions.

Who the reference helps most

The form suits any setting where more than one clinician prescribes for lipids:

• Primary care and family medicine practices managing dyslipidemia across a large panel.
• Cardiologists coordinating pharmacotherapy for high-risk patients with several lipid disorders.
• Endocrinologists treating hypertriglyceridemia secondary to diabetes or metabolic syndrome.
• Multi-location groups that need one prescribing standard across every site.
• Nurse practitioners and physician assistants using it as a decision-support sheet.
• Pharmacists verifying prescriptions and counseling patients on side effects.

Benefits of a standardized medication reference

• Consistent documentation. Fixed fields make every prescriber record the same details, which cuts transcription errors when several clinicians share a patient.
• Faster decisions. Current dosing and monitoring parameters sit at the point of care, so nobody looks them up mid-consultation.
• Safer prescribing. One view of every agent, its side effects, and its interactions makes the statin-fibrate combination harder to miss.
• Audit readiness. A dated list plus the matching monitoring results shows that each prescribing decision was evidence-based and followed up.

How Pabau keeps the medication list beside the prescription

Most practices keep a reference like this as a PDF on a shared drive, or as a printout at the nurses’ station. The prescriber reads it in one place and writes the prescription in another, and the two records drift apart within a few review cycles.

Practice management software like Pabau closes that distance. The list lives as a digital form attached to the patient record, beside the lipid panel, the current regimen, and the monitoring schedule.

Prescribing happens in the same record. A switch from gemfibrozil to fenofibrate is written, logged, and visible to whoever sees the patient next. Automated reminders book the 6 to 12 week lipid panel at the moment the prescription is issued.

Your practice ends up with one current regimen per patient, and the monitoring dates attached to it rather than held in somebody’s memory.

Keep prescribing references inside the patient record

Pabau holds this medication list as a digital form on the patient record, beside the lipid panel and the prescription. Monitoring reminders are booked as the script is issued.

Book a demo

Conclusion

Prescribing for hypertriglyceridemia turns on three questions. How high is the level, is a statin already in play, and what will the patient tolerate? The classes answering those questions have barely changed in a decade, but their evidence has.

Vascepa gained a cardiovascular claim, niacin lost the argument for adding it to a statin, and two brand products left the US market. That churn is the case for a dated, maintained list instead of recall.

Review the sheet once a year against FDA prescribing information, and keep it where the prescription is written rather than in a folder. Book a demo to see how Pabau keeps prescribing references and monitoring schedules inside the patient record.

Continue your research

Treating lipids and glucose in the same patient? The diabetes medication list covers the glucose-lowering agents you will be prescribing alongside a fibrate.

Deciding between diet and a prescription? Lifestyle versus pharmacologic interventions sets out when each one earns its place in metabolic care.

Need something to hand the patient after the consultation? The low cholesterol diet plan gives them a structured week of meals to work from.

Screening before the panel comes back? At-home cholesterol testing explains what those kits measure and where they fall short of a lab lipid panel.

Frequently asked questions